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This is an open access artipatients [1,2]. Since the description of the type species,
A. xylosoxidans [3], 14 other species have been ranked into the
genus Achromobacter: A. piechaudii and A. ruhlandii [4],
A. denitriﬁcans [5], A. spanius and A. insolitus [6], A. marplatensis
[7], A. animicus, A. mucicolens, A. pulmonis and A. spiritinus [8],
A. insuavis, A. aegrifaciens, A. anxifer and A. dolens [9], and 6 other
genogroups. These 21 species and genogroups can be distin-
guished by the multilocus sequence typing (MLST) scheme
proposed by Spilker et al. [10]. The study demonstrated that
sequencing a 765 bp internal fragment of the only nrdA gene is
sufﬁcient for correct identiﬁcation [11]. Because of the actual
difﬁculty in performing accurate species identiﬁcation, most
isolates are still referred by default as A. xylosoxidans, preventing
the evaluation of the real epidemiology and clinical impact of
each species. Moreover, the data about the mechanisms of
innate antibiotic resistance are scarce [12,13]. The AxyXY-
OprZ RND efﬂux system confers resistance to aminoglyco-
sides (AG) in A. xylosoxidans AXX-A since reclassiﬁed as
A. insuavis (accession number AFRQ01000000). Nevertheless,
AG, which take an important part in CF antimicrobial therapy,
remain active against some isolates of Achromobacter spp.
[14,15].We sought to describe the distribution of AG-resistant
isolates among the different species of the genus Achromo-
bacter and to search for the axyXY-oprZ efﬂux operon in
AG-resistant and -susceptible isolates to assess if AG resistance
is correlated with the presence of the operon.
Forty-nine Achromobacter isolates harbouring various AG
resistance patterns were included in this study: 21 from CF
patients’ sputum, 20 from non-CF clinical samples and eight
from environmental samples (Table 1). Most of them (n = 35)
were collected in our laboratory; nine collection strains were
purchased from the Institut Pasteur, France, including six type
strains, and ﬁve were kindly provided by J. J. LiPuma (Depart-
ment of Pediatrics and Communicable Diseases, University of
Michigan Medical School). Isolates were identiﬁed at the genus
level either by using the conventional biochemical method API
20NE (bioMérieux) or by sequencing the 16S rRNA gene. The
identiﬁcation to the species level was performed by sequencing
the 765 bp internal nrdA fragment followed by Achromobacter
PubMLST database query (http://pubmlst.org/achromobacter/).
Minimal inhibitory concentrations (MICs) of tobramycin, ami-
kacin, gentamicin and netilmicin were measured by the Etest
method (bioMérieux). Mueller-Hinton agar plates were inocu-
lated by swabbing from a 0.5 McFarland turbidity bacterial
suspension, and MICs were recorded after overnight incubation
at 37°C by two persons independently. The phenotype “AG-
susceptible” (AG-S) was attributed to isolates susceptible to allNew Microbe and New Infect 2016; 10: 1–5
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TABLE 1. Achromobacter isolates and main results
nrdA identiﬁcation Isolate Origin
MIC (mg/L)
AG
S/R
PCR
axyY
PCR
oprZTOB AMK GEN NET
A. aegrifaciens ACH-CF-D59 CF sputuma >256 >256 >256 >256 R + +
A. aegrifaciens ACH-CF-802 CF sputuma 64 48 16 32 R + +
A. aegrifaciens ACH-ENV-2 Hospital hand-washing sinka 12 8 3 8 R + +
A. aegrifaciens ACH-CF-766 CF sputuma 192 48 12 64 R + +
A. animicus ACH-CF-864 CF sputuma 1.5 4 1 1 S − −
A. animicus ACH-NCF-33 Cathetera 1.5 6 2 2 S − −
A. animicus ACH-CF-D63 CF sputuma 1.5 4 1.5 1 S − −
A. animicus ACH-CF-D64 CF sputuma 2 8 2 1.5 S − −
A. animicus ACH-CF-D65 CF sputuma 1 3 1.5 1.5 S − −
A. animicus ACH-CF-711 CF sputuma 2 4 1.5 1.5 S − −
A. denitriﬁcans CIP-77.15T Soil 32 256 64 64 R + +
A. dolens AU18822 CF sputum >256 64 >256 12 R + +
A. dolens AU20310 CF sputum >256 >256 >256 128 R + +
A. genogroup 12 ACH-ENV-3 Dialysis watera 3 32 8 8 R + +
Novel species ACH-CF-583 CF sputuma 24 >256 96 >256 R + +
A. insolitus CIP-108202T Leg wound 256 32 48 >256 R + +
A. insuavis ACH-CF-476 CF sputuma >256 >256 >256 >256 R + +
A. insuavis ACH-CF-777 CF sputuma 96 >256 >256 >256 R + +
A. insuavis AXX-A Ear swaba 16 256 24 64 R + +
A. insuavis CIP-102062 Blood 12 256 16 24 R + +
A. marplatensis ACH-ENV-4 Lakea 12 256 24 32 R + +
A. mucicolens ACH-NCF-34 Tracheal aspiratea 1.5 6 1.5 1.5 S − −
A. mucicolens ACH-NCF-35 Tracheal aspiratea 2 8 2 1.5 S − −
A. mucicolens ACH-NCF-36 Blooda 2 6 2 2 S − −
A. mucicolens ACH-CF-510 CF sputuma 2 8 2 2 S − −
A. piechaudii CIP-60.75T Pharynx 1.5 6 3 3 S − −
A. ruhlandii CIP-77.26T Soil 8 24 12 16 R + +
A. ruhlandii AU19877 CF sputum 16 >256 48 64 R + +
A. ruhlandii AU19911 CF sputum 3 48 6 12 R + +
A. ruhlandii AU19929 CF sputum >256 >256 >256 >256 R + +
A. spanius CIP-108199T Blood 1.5 6 4 4 S − −
A. spanius ACH-NCF-37 Foot wounda 1 4 1 1.5 S − −
A. spanius ACH-CF-746 CF sputuma 2 6 2 2 S − −
A. xylosoxidans ACH-CF-809 CF sputuma 128 >256 256 >256 R + +
A. xylosoxidans ACH-NCF-39 Insertion-site skin swaba 24 >256 64 128 R + +
A. xylosoxidans ACH-NCF-18 Tracheal aspiratea 64 >256 128 256 R + +
A. xylosoxidans CIP-71.32T Ear discharge 192 >256 >256 >256 R + +
A. xylosoxidans CIP-101902 Pleural ﬂuid >256 >256 >256 >256 R + +
A. xylosoxidans CIP-102236 Sputum 48 >256 256 >256 R + +
A. xylosoxidans ACH-NCF-41 Sputuma 32 >256 64 128 R + +
A. xylosoxidans ACH-NCF-42 Tracheal aspiratea 8 256 24 64 R + +
A. xylosoxidans ACH-ENV-1 Dental instrumenta 192 >256 >256 >256 R + +
A. xylosoxidans ACH-NCF-13 Bronchial aspiratea 64 >256 128 >256 R + +
A. xylosoxidans ACH-CF-805 CF sputuma 24 >256 48 192 R + +
A. xylosoxidans ACH-NCF-11 Sputuma 16 256 32 48 R + +
A. xylosoxidans ACH-CF-842 CF sputuma 8 192 24 32 R + +
A. xylosoxidans ACH-NCF-40 Blooda 32 >256 96 192 R + +
A. xylosoxidans ACH-ENV-5 Rivera 16 >256 24 64 R + +
A. xylosoxidans ACH-ENV-6 Domestic hand-washing sinka 32 >256 48 128 R + +
AG, aminoglycoside; AMK, amikacin; CF, cystic ﬁbrosis; GEN, gentamicin; MIC, minimum inhibitory concentration; NET, netilmicin; R, resistant.; S, susceptible; TOB, tobramycin.
aIsolates collected in our laboratory.
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using the European Committee on Antimicrobial Susceptibility
Testing clinical breakpoints for Pseudomonas spp. (http://www.
eucast.org/clinical_breakpoints/; version 5.0). Detection of the
axyXY-oprZ operon was performed by 2 PCRs targeting the
genes (a) axyY, encoding the RND transporter, and (b) oprZ,
encoding the outer membrane factor. PCRs were carried out in
reaction mixtures containing dNTP (0.2 mM), forward and
reverse primers (0.25 μM each), Taq polymerase (Fermentas)
(2.5 U) with the supplied buffer, MgCl2 (1.5 mM), dimethyl
sulfoxide (5% volume) and template DNA (1 μL), adjusted with
water to a ﬁnal volume of 50 μL. The cycling parameters were
94°C for 10 minutes, 30 cycles of 94°C for 90 seconds,
annealing primers temperature for 90 sections, 72°C for 60New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceseconds, and 72°C for 10 minutes. The results are summarized
in Table 1.
The nrdA sequences analysis allowed identiﬁcation of 48 of
the 49 isolates. nrdA sequence of ACH-CF-583 harboured 39
nucleotide differences, with its closest match in database
(genogroup 19) (Fig. 1) indicating that this isolate belonged to a
novel genogroup or a novel species. Fourteen of the 49 studied
isolates were categorized as AG-S. Interestingly, all isolates
belonging to a same species harboured the same AG resistance
pattern. In the resistant species, the level of resistance was
sometimes variable among the isolates. Nevertheless, none of
these isolates had been categorized as susceptible for all four
AG molecules. A variable expression level of the efﬂux operon
might account for these differences as already observed forEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 10, 1–5
nses/by-nc-nd/4.0/)
FIG. 1. ACH-CF-583 nrdA sequence alignment with its closest match (genogroup 19) in Achromobacter PubMLST database. Query: ACH-CF-583;
Ref: closest match in database.
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AG-R isolates according to species identiﬁcation is repre-
sented in a dendrogram (Fig. 2) generated from the nrdA se-
quences using the neighbour-joining method with 1000
bootstrap replications (MEGA6). We also included in the
dendrogram the nrdA sequences of the type strains (LMG) of
the recently described novel species. AG-S isolates were
divided up into two clusters of species including A. animicus and
A. mucicolens (cluster 1), and A. spanius and A. piechaudii (cluster
2). These two clusters were supported by high bootstrap
values. All other isolates were AG-R and did not belong to
cluster 1 or 2. They included the 16 A. xylosoxidans isolates and
all isolates from the species A. aegrifaciens, A. denitriﬁcans, A.
dolens, A. genogroup 12, A. insolitus, A. insuavis, A. marplatensis
and A. ruhlandii. A similar tree topology was obtained by using
the maximum likelihood and the maximum parsimony methods
(data not shown). There was a perfect correlation between the
AG resistance proﬁle and the presence of the AxyXY-OprZ
efﬂux system. Indeed, the operon was detected in all AG-R
isolates and not in the AG-S ones. An additional PCR was
performed in all AG-S isolates with primers designed in
ﬂanking sequences of the axyXY-oprZ operon and conﬁrmed
the absence of the whole operon. Because the GC content of
the efﬂux operon is similar to that of whole genome, we hy-
pothesized that a deletion occurred in the course of evolution.New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beh
This is an open access artiThese ﬁndings indicate that susceptibility or resistance to AG
might be a phenotypic trait correlated with Achromobacter
species evolution.
To date, and to our knowledge, only four studies including
an appropriate Achromobacter identiﬁcation method report
distribution of the different Achromobacter species in clinical
samples. They indicate that A. xylosoxidans is the species the
most frequently recovered from CF patients [11,17–19].
Other species are also widely prevalent: A. ruhlandii, A. dolens
and A. insuavis. It is noteworthy that all isolates belonging to
these four species have been categorized as AG-R in the
present work. One can therefore wonder whether these AG-R
species are more pathogenic than the AG-S ones, which might
explain their high prevalence. One might also hypothesize that
these species have emerged under the selection pressure of
AG treatment frequently prescribed to those in the CF
population.
In conclusion, AG resistance is the ﬁrst phenotypic charac-
teristic correlated with the different species of the genus Ach-
romobacter. More studies including accurate species level
identiﬁcation are required in order to improve knowledge
about the epidemiology and virulence of these pathogens. They
might also help to elucidate whether the use of inhaled AG
promotes selection of Achromobacter that belong to the species
harbouring the AxyXY-OprZ efﬂux system.alf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 10, 1–5
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FIG. 2. Neighbour-joining dendrogram based on nrdA sequence. Numbers at nodes indicate bootstrap values. Scale bar indicates number of sub-
stitutions per site. AG-resistant (AG-R) isolates are in upper box; AG-susceptible (AG-S) isolates are in boxes ‘cluster 1’ and ‘cluster 2.’ AG resistance
was not determined for the LMG strains.
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